

February 5, 9:30 a.m., it is proposed that members of the special committee of the Royal College of Physicians and Surgeons, drug investigation committee, Dr. S. S. Brien, chairman, Dr. E. A. Sellars, and Dr. R. Dufresne be called to give witness pertaining to their report, which by that time will have been in our hands as I believe it is going to be tabled in the house today.

On February 6, 9:30 a.m. and February 7, 9:30 a.m., we will continue with discussions, if necessary, of the investigation of the committee as I mentioned above.

February 12 and 13, we will visit Montreal to see first hand clinical research and manufacturing facilities, to include units at the Hôtel-Dieu hospital under the directorship of Dr. Jacques Genest, Ayerst, McKenna and Harrison Limited, biological and pharmaceutical chemists, and Charles E. Frosst and Company, and their Kimm laboratories.

February 14—we can have a discussion on that later. I do not think the committee should crowd its hearings because if we bring witnesses from all over the country or from the United States or anywhere else, we should leave ample room in which to give them consideration so that they will not have to stay here for two or three weeks.

Mr. HADASZ: Are we going to be allowed to discuss this agenda later?

The CHAIRMAN: Yes; at the end of the discussion I want to throw the whole section open for discussion on drug safety and on the agenda.

February 19, 9:30 a.m., start receiving evidence from professional associations, trade associations and professional individuals, all relating to section "A" of the terms of reference. "The law and practices relating to the control of the introduction, marketing and use of drugs." (safety)

February 26, 9:30 a.m., Mr. Paul Blanc, World Health Organization, Geneva, Switzerland who has kindly consented to come that week, if we want him to.

Meetings in future will be determined at a later date.

Can we now have a discussion on the agenda as outlined? The reason we kept the special associations and professional people off until February 19 is that we wanted the permission of this committee to notify all the proposed witnesses of our intention to ask them, thereby giving them ample time to prepare their statements or reports to this committee. We thought that by having the departmental officials and the special committee of the Royal College of Physicians and Surgeons, first we would do this in a very orderly way. Could we have a discussion of the schedule, or would you like an over-all discussion of the drug situation?

Mr. MITCHELL: If I might intervene here for a moment, when you spoke of government officials I noticed that R. C. Hammond was not included in your group. As you know, he is the director of narcotic control, and under his direction are the special schedule G drugs. This is very necessary for this committee's information.

The CHAIRMAN: This was discussed, and I did not propose a list of all the people within the Department of National Health and Welfare pertaining to this problem because I thought that when the minister made a statement he would have all the people pertaining to every section of the legislation under his administration with him and they could give us a list of the people that are necessary to investigate this problem completely.

Mr. MITCHELL: He would be included under the food and drug directorate.

Mr. HADASZ: I was just going to make a statement on the schedule of meetings, and specifically the meetings scheduled for February 12 and 13—visits to Montreal.